US 9730930
Treatment for vitiligo
granted A61KA61K31/145A61K31/505
Quick answer
US patent 9730930 (Treatment for vitiligo) held by Rigel Pharmaceuticals, Inc. expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K31/145, A61K31/505, A61K31/506, A61K45/06